Nusano (previously known as Alpha Source Inc./Alpha Isotopes) filed paperwork with the United States Securities and Exchange Commission on October 24, 2018 detailing a $41 million seed funding round from investors.
With its patented technology, Nusano is working to transform the production of medical-grade radioisotopes to enable advancements in cancer treatment and health care.
Read more in the Los Angeles Business Journal
VALENCIA, Calif. – November 12, 2024 – Nusano, a physics company transforming the production of radioisotopes, today...
Image above: Starget Pharma, stargetpharma.comVALENCIA, Calif. and TEL AVIV, Israel – Oct. 17, 2024 – Nusano, a...
VALENCIA, Calif. – Oct. 7, 2024 – Nusano, Inc., a physics company transforming the production of radioisotopes, today...
VALENCIA, Calif. – Oct. 3, 2024 – Nusano, Inc., a physics company transforming the production of medical...
Funding supports development and commercialization of broad array of isotopes for medical, commercial and industrial...
September 2024 – Insights Care recently interviewed Nusano CEO Chris Lowe for its "5 Most Trusted Radiopharmaceutical...
Sign up to receive company news and updates